CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project is focused on developing OMO-103, a novel treatment for pancreatic cancer that selectively inhibits the MYC protein, which is crucial for cancer cell survival. The drug has shown promising results in early clinical trials, demonstrating safety and potential effectiveness in reducing tumor size and stabiliz…
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options.
Despite recent advances, cancer therapies remain ineffective and/or highly toxic.
Our approach is targeting MYC, a function essential to cancer cells that allows them to survive and develop resistance to therapy.
In contrast to standard drugs, inhibiting MYC selectively blocks tumor progression without causing important side effects. MYC has been considered undrugga…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
